Aristides Capital’s Pyxis Oncology PYXS Stock Holding History

Aristides Capital’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-124,000	Closed	-$193K	–	315
2024 Q4	$193K	Buy	+124,000	New	+$358K	0.04%	248

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Aristides Capital's PYXS Position: Q1 2025 in Review

Aristides Capital sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 124,000 shares — an estimated $193K sold.

Aristides Capital first reported a position in PYXS in Q4 2024 and held it in 1 quarter. The position peaked at $193K in Q4 2024. 88 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

Aristides Capital reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 124,000 Pyxis Oncology shares in Q1 2025, an estimated $193K.
Aristides Capital first reported a position in Pyxis Oncology in Q4 2024 and held it in 1 quarter.
Aristides Capital's Pyxis Oncology position peaked at $193K in Q4 2024.
88 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.